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Abstract
Background: Carbon nanotubes (CNTs) have found wide success in circuitry, photovoltaics, and other applications. In
contrast, several hurdles exist in using CNTs towards applications in drug delivery. Raw, non-modified CNTs are widely
known for their toxicity. As such, many have attempted to reduce CNT toxicity for intravenous drug delivery purposes by
post-process surface modification. Alternatively, a novel sphere-like carbon nanocapsule (CNC) developed by the arc-
discharge method holds similar electric and thermal conductivities, as well as high strength. This study investigated the
systemic toxicity and biocompatibility of different non-surface modified carbon nanomaterials in mice, including multi-
walled carbon nanotubes (MWCNTs), single-walled carbon nanotubes (SWCNTs), carbon nanocapsules (CNCs), and C60
fullerene (C60). The retention of the nanomaterials and systemic effects after intravenous injections were studied.
Methodology and Principal Findings: MWCNTs, SWCNTs, CNCs, and C60 were injected intravenously into FVB mice and
then sacrificed for tissue section examination. Inflammatory cytokine levels were evaluated with ELISA. Mice receiving
injection of MWCNTs or SWCNTs at 50 mg/g b.w. died while C60 injected group survived at a 50% rate. Surprisingly, mortality
rate of mice injected with CNCs was only at 10%. Tissue sections revealed that most carbon nanomaterials retained in the
lung. Furthermore, serum and lung-tissue cytokine levels did not reveal any inflammatory response compared to those in
mice receiving normal saline injection.
Conclusion: Carbon nanocapsules are more biocompatible than other carbon nanomaterials and are more suitable for
intravenous drug delivery. These results indicate potential biomedical use of non-surface modified carbon allotrope.
Additionally, functionalization of the carbon nanocapsules could further enhance dispersion and biocompatibility for
intravenous injection.
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The superior electrical and thermal conductivities, optical
properties, and mechanical strength of carbon nanotubes (CNTs)
and C60 fullerene (C60) make these nanomaterials ideal for use in
structural supports, circuits, biosensors, batteries and solar cells
[1,2]. Different forms of fullerene have been envisioned as
components of potential therapeutic devices in which they might
act as tissue scaffolds 3, implants [4], biological microelectrome-
chanical systems, biosensors, medical contrast agents, and drug
delivery carriers [5–8]. Accordingly, the toxicology of CNTs has
been widely investigated to understand the biological effects of
these nanomaterials. Previous studies have demonstrated the in vivo
toxicity and poor biocompatibility of multi-walled CNTs
(MWCNTs), single-walled CNTs (SWCNTs) [9,10] and C60 11
following inhalation 12, intratracheal instillation 13 or intraper-
itoneal injection [15–18].
Nanomaterials have been investigated as a technology to deliver
therapeutic agents within the body with the ability to bypass tough
biological barriers 19. Like most nanomaterials, the dimensions of
CNTs are on the nanoscale, providing a high surface-area-to-
volume ratio for efficient drug conjugation or encapsulation.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32893Because great interest in using fullerenes for drug delivery has
been generated, different forms of these carbon nanomaterials
have been developed. To effectively use these nanomaterials for
drug delivery, the biocompatibility and toxicity of these nanoma-
terials within biological systems must be fully characterized and
understood [20]. Several reviews and studies have reported the
toxicity of unmodified MWCNTs, SWCNTs, and C60 [9–
13,17,18,20]. The van der Waals forces on the surfaces of pristine
CNTs cause hydrophobic interactions between CNTs, resulting in
unwanted aggregation, agglomeration and wiring[9,18,20]. To
avoid excessive surface interactions and to decrease toxicity,
studies have opted to cut and extensively surface-modify CNTs for
enhanced biocompatibility [4–10,15–18,20]. Despite so, over-
whelming toxicological reports of CNTs have given rise to the
consensus that these long and rigid CNTs are not suitable for in
vivo applications [10]. Though surface modifications do in fact
reduce toxicity to certain degree, the extensive act of functiona-
lization and related modifications is simply masking the root cause
of toxicity of CNTs, derived from the material’s surface.
Recently, carbon nanocapsules (CNCs) have emerged as a novel
carbon-based nanomaterial synthesized in a manner similar to that
used for CNTs and C60 [21,22], providing comparable chemical
composition, and electrical, thermal, and mechanical character-
istics. Following the footsteps of CNTs, CNCs have also found
success in different applications, including transceiver modules and
photovoltaics [23,24,25]. In contrast, biomedical applications
using CNCs have not yet been attempted. A major difference,
namely the aspect ratio, exists in the spherical geometry of CNCs,
compared to long, tangling characteristics of CNTs. Intuitively,
the low aspect ratio structure of CNCs are more dynamically
suitable for in vivo delivery. Herein, we investigate the in vivo
biocompatibility of non-modified CNCs, MWCNTs, SWCNTs,
and C60 in mice, providing insight into advantages of using carbon
nanocapsules for systemic drug delivery.
Materials and Methods
Ethics Statement
All animal procedures were approved by the National Cheng
Kung University Institutional Animal Care and Use Committee.
Carbon nanomaterial preparation
The CNCs were prepared as described previously [21,22].
Briefly, an inert gas (helium, argon, or nitrogen), was introduced
into an arc chamber containing a graphitic cathode and anode. A
current was then introduced to the chamber that had sufficient
voltage (10–30 V) for a carbon arc reaction to take place. The rate
of the inert gas was controlled to approximately 60 to 90 cm
3/
min, and the chamber pressure was maintained between 1 and
2 atm. A pulse current was used (50–70 Hz; 50–500 A), and the
deposit on the cathode was collected and passed through a 0.22
mm filter for purification. The deposits contained roughly 70%
CNCs before purification and at least 95% after purification.
MWCNTs were produced in a similar manner using the arc-
discharge method under an argon atmosphere, as previously
described [23]. A direct current electric field was applied, and
deposits were collected from the cathode and purified. The
deposits were roughly 50% pure and became more than 95% pure
after purification. SWCNTs were purchased from SES research
(Texas, USA) and C60 from Sigma Aldrich (Missouri, USA). All
carbon nanomaterials were dispersed in 1 wt % polyvinyl alcohol
(PVA) at 5–10 mg/ml. Immediately before injection, the nano-
material dispersions were sonicated for 1 h (E60H, Elma
Ultrasonics, Germany).
TEM analysis
Carbon nanoparticles were dispersed in 1% PVA onto
Formvar/carbon-coated 200 mesh copper grids (Ted Pella Inc,
CA, USA) for TEM analysis using an H-7500 TEM (Hitachi,
Japan). The samples were lyophilized for 24 h and imaged by an
experienced technician.
Animal protocols and experiments
The investigation conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996). Adult FVB
mice 8 to 12 weeks old and weighing 20 to 28 g were used in this
study. The mice were anesthetized with sodium pentobarbital
(50 mg/kg, i.p.). After the anesthetic had taken effect, the mice
were injected with normal saline, 1% PVA, CNCs, C60, SWCNTs,
or MWCNTs at a dose of 50, 25 or 12.5 mg/g bw via the tail vein,
comparable to previous studies [26–28]. Normal saline and 1%
PVA were injected at the same volume as the nanomaterials.
Nanomaterials were injected at a diluted concentration so that
each injection was approximately 200–250 ml (injection volume
varied due to animal weight variations). A gauge was used to stop
the bleeding of the tail, and the mice were allowed to recover from
anesthesia in cages in a temperature- and climate-controlled
environment with food and water. Mice were deeply anesthetized
prior to sacrifice by cervical dislocation at different time points for
organ harvesting and urine and blood collection. Blood collection
was performed by cardiac puncture prior to cervical dislocation.
Mouse survival study
Mice were separated into three dosage groups with 11 or 12
mice in each group. The carbon nanomaterials were sonicated for
1 h prior to injection, and a total volume of 200–250 ml was
injected into each mouse (injection volume varied due to animal
weight variations). Nanomaterials were diluted with 1% PVA to
maintain similar injection volumes for all three doses. After
injection, mice were returned to their cages to recover from the
anesthesia in a temperature- and climate-controlled environment.
The mice were monitored closely for the first 6 hours, at 12 hours,
and then every day following the first day. The time of death of
each mouse was recorded, and at the end of 7 d, the mice were
sacrificed, and their organs were harvested for tissue sectioning.
Tissue sections and nanomaterial retention
quantification
Organs were harvested 6 h or 7 d after injection with the
nanomaterials, washed in PBS and fixed in 4% paraformaldehyde
at 4uC overnight. The organs were then stored in 70% ethanol
prior to paraffin embedding. Sections were stained with hema-
toxylin and imaged using an Axio Scope A1 imaging system (Carl
Zeiss). For the nanomaterial retention study, at least 2 tissue
sections from each lung were used and were left unstained to
reduce background and false positive signals. Whole tissue sections
were imaged by HistoFAXS (TissueGnostics, Austria) at a 200x
final magnification and were analyzed with HistoQuest (TissueG-
nostics, Austria) for automated structure detection, automatic
color separation, and quantification.
Inflammatory cytokine study
Blood was collected from mice 6 hours post-injection and was
allowed to sit at room temperature for at least 1 h. Lipopolysac-
charide (LPS) injected intravenously served as positive control
(5 mg/kg, sigma). Samples were centrifuged at 1500 g for
10 minutes to obtain serum. Serum samples were then analyzed
Carbon Nanomaterial Toxicity
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32893Figure 1. Mouse survival curves after carbon nanomaterial injection. (A) TEM analysis of carbon nanocapsules (CNCs), C60 fullerene (C60),
multi-walled carbon nanotubes (MWCNTs), and single-walled carbon nanotubes (SWCNTs) dispersed in 1% polyvinyl alcohol (PVA). SWCNTs formed
large networks, and MWCNTs aggregated compactly. CNCs were well dispersed in PVA, while C60 aggregated to size as large as CNCs. The scale bar is
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detection of cytokines. These assays were performed according to
the manufacturer’s instructions (AssayPro, USA). Normal saline
was used as a negative control, and lipopolysaccharide was used as
a positive control. Lung tissues were also collected 6 hours post-
injection and homogenized in 500 ml of lysis buffer containing
protease inhibitors. Homogenized samples were centrifuged at
14,000 RPM for 20 minutes to remove debris. The supernatants
were analyzed using ELISA kits for mouse IL-1b and mouse IL-6
for the detection of cytokines. Cytokine levels were normalized
to the total protein level determined by the BCA assay (Pierce,
USA).
Statistical Analysis
All data are presented as the mean6sem. Data were analyzed
by one-way ANOVA followed by Tukey’s post hoc test using
Prism 5 (GraphPad, USA). A value of P,0.05 was considered
statistically significant.
Results
Physical characteristics of carbon nanomaterials
Non-modified CNTs, whether single-walled (SWCNT) or multi-
walled (MWCNT), form networks and aggregates even when
dispersed in a surfactant such as PVA (Fig. 1a). The tube diameter
of MWCNT were approximately 25 nm measured from TEM
images. SWCNT diameters ranged from 2 nm to 25 nm
(Table S1). C60, though much more uniform and dispersed than
CNTs, still aggregated, forming 100 nm in diameter clusters. C60
molecules have a very low solubility and an extremely high
density. Therefore, these nanoparticles settle within minutes even
when dispersed in PVA after sonication and mixing (Figure S1).
CNCs were much more uniformly dispersed and each particle was
approximately 50 nm in diameter (Fig. 1a).
In vivo toxicity of carbon nanomaterials and cause of
death
To study the in vivo toxicity of carbon nanomaterials, different
carbon nanomaterials were intravenously injected into mice at
three different doses. Strikingly, none of the mice receiving 50 mg/
g b.w. of either MWCNTs or SWCNTs survived (n=11 for each).
By contrast, mice injected with CNCs had a 91.7% survival rate
(n=12), while half of the mice injected with C60 died (6 out of
n=12; Fig. 1b). The toxicities of the nanomaterials were dose
dependent, as shown by the survival curves for the three different
doses (Fig. 1b). Interestingly, all of the mice injected with 25 and
12.5 mg/g b.w. of CNCs survived, while some of the mice injected
with these doses of MWCNTs or SWCNTs died (Fig. 1b).
Postmortem inspections of the mice receiving 50 mg/g doses
revealed that CNTs were clearly visible in the lungs (Fig. 2a). As
expected, the MWCNT- and SWCNT-injected groups had the
darkest lungs, which were fully covered with black spots. Lungs
from CNC- and C60-injected mice generally exhibited a pink hue
similar to that of the normal saline and 1% PVA in deionized H2O
(PVA) groups, both of which served as controls (Fig. 2a). Tissue
sections of these lungs further revealed that a large surface area of
MWCNT and SWCNT lungs was occupied by CNTs (Fig. 2b).
Biodistribution and retention of carbon nanomaterials
To quantify and compare the retention of the carbon
nanomaterials in the lungs, surviving mice from the 25 mg/g dose
injections were sacrificed on day 7, and the lungs were collected
for tissue section analysis. Similar to injections of 50 mg/g, lung
tissue sections from mice injected with 25 mg/g showed a similar
trend in the lung retention of the nanomaterials. MWCNTs and
SWCNTs were widely distributed and accumulated in the lungs,
100 nm. (B) Cumulative deaths of mice intravenously injected with different doses of carbon nanomaterials. SWCNTs and MWCNTs had the highest
toxicity, which was dose dependent, decreasing as the dose of the carbon nanomaterials decreased. No mortality was observed among the CNC-
treated mice at 25 mg/g b.w. n=12 for CNC, and C60 injected mice. n=11 for NS, PVA, MWCNT, and SWCNT injected mice. Red square, 50 mg/g; black
dot, 25 mg/g; black cross, 12.5 mg/g.
doi:10.1371/journal.pone.0032893.g001
Figure 2. Lung tissues and lung tissue sections after carbon
nanomaterial injection. (A) Excised lungs 10 min after mice were
injected with 50 mg/g b.w. of different carbon nanomaterials. (B) Lung
tissue sections 10 min after mice were injected with 50 mg/g b.w. of
different carbon nanomaterials. Mice receiving C60 fullerene (C60), multi-
walled carbon nanotubes (MWCNTs), and single-walled carbon
nanotubes (SWCNTs) died within 10 minutes, and only mice in the
carbon nanocapsule (CNC), normal saline, and polyvinyl alcohol (PVA)
groups had to be sacrificed. Tissue sections were stained with
hematoxylin. The scale bar is 400 mm.
doi:10.1371/journal.pone.0032893.g002
Carbon Nanomaterial Toxicity
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32893while CNCs and C60 were scarce (Fig. 3a). Automated microscopic
whole tissue section analysis revealed that MWCNTs retained in
the lungs by more than a factor of 14 compared to CNCs or C60,
while SWCNTs retained by a factor of more than 30 (Fig. 3b).
Because CNTs formed larger aggregates in the range of 200–1000
nm (Fig. 1), more blood vessels were observed to be have been
clogged by MWCNTs and SWCNTs (Fig. 3a). By contrast, CNCs
and C60 did not form aggregates larger than 200 nm; therefore,
they passed through to other organs including the liver, spleen,
and kidney, or cleared through the renal system (Fig. 4, Figure S2).
SWCNTs were lethal even at the dose of 12.5 mg/g following
systemic injection, and retention was found to be twice that of
MWCNTs in the lungs.
Systemic inflammatory response after IV injection of
carbon nanomaterials
Although CNTs and nanoparticles have the potential to be used
for drug delivery applications, the foreign body reaction of
nanomaterials is a concern. Nanotoxicity arises from the
inflammatory responses to foreign bodies, cellular uptake and
inflammatory cytokine production, among many other acute
responses [29,30]. Interleukin–1 beta (IL-1b) and interleukin–6
Figure 3. Carbon nanomaterial retention in the lungs. (A) Lung tissue sections of mice 7 days after intravenous injection with carbon
nanomaterials at 25 mg/g b.w. (B) Automatic carbon nanomaterial retention quantification in the lungs. High-magnification images (red-bordered
images) show large carbon nanotube aggregates blocking the blood vessels of the lungs (arrows). SWCNTs and MWCNTs were retained in the lungs
at much higher rates compared to CNCs or C60. Tissue sections were stained with hematoxylin. Scale bar=100 mm. ***P,0.0001 compared to CNCs
and C60, n=4 in all groups. NS, normal saline; PVA, polyvinyl alcohol; CNCs, carbon nanocapsules; C60,C 60 fullerene; MWCNTs, multi-walled carbon
nanotubes; SWCNTs, single-walled carbon nanotubes.
doi:10.1371/journal.pone.0032893.g003
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inflammation that mediate the inflammatory response. To
examine the acute systemic response after injecting the nanoma-
terials, serum was collected from the surviving mice for an ELISA
analysis. Lipopolysaccharide (LPS) served as a positive control for
inducing systemic inflammatory cytokines. Serum from all groups
of injections showed no significant difference with each other in
IL-1b and IL-6 expression levels (Fig. 5). Furthermore, the
cytokine levels in the lung tissue samples also showed the same
result (Fig. 6). LPS injected samples, both serum and lung tissue,
were significantly were significantly higher in both IL-1b and IL-6.
Pellets from lung-tissue preparation for cytokine detection revealed
consistent results from tissue sections (Figure S3). MWCNT and
SWCNT lung homogenates were extremely dark while CNC and
C60 groups were much lighter in color.
Discussion
Although nanoscopic in feature size, pristine CNT surfaces
strongly attract each other through van der Waals forces, causing
aggregation and network formation [5,9,18,20]. This non-
dispersing interaction prevents CNT from being an ideal tool for
drug delivery through intravenous injection [18,20]. Consistent
with previous studies, we found that CNTs were prone to
aggregate and easily bundled on itself [10]. To overcome the
challenging aggregate-forming surface properties of CNTs,
previous studies have put effort in cutting, functionalizing, and
surface modifying CNTs [4–10,15–18,20]. However, surface
modification is rather masking an existing flaw of CNT toxicity
instead of actually eliminating this shortcoming. Most studies using
CNTs for drug delivery purposes require cutting to reduce the
overall length. However, in this form, CNTs are still too long and
rigid drug delivery purposes [10]. Furthermore, different fabrica-
tion protocols introduce defects as part of the process, whether
intentionally or as a side effect [31,32]. These structural defects
have been linked to causing acute lung toxicity, genotoxicity, and
inflammatory responses [33–36]. Recently, CNCs have been
produced using a method similar to that used for preparing CNTs
using a pulsed plasma arc discharge method [21,22]. Much like
CNTs, CNCs have high electrical conductivity, thermal conduc-
tivity, strength, and surface-area-to-volume ratio [37]. However,
CNCs differ from CNTs in that CNCs inherently have a much
lower aspect ratio at around 1.5. Furthermore, CNCs are
uniformly synthesized nanoparticles ranging from 40–60 nm while
highly dense C60 form clusters up to 100 nm. Due to the
previously mentioned properties, CNCs, unlike CNTs and C60,
lack aggregating properties, which are much more favorably
biocompatible for drug delivery purposes.
Figure 4. Carbon nanomaterial retention in vital organs. Liver, spleen, and kidney tissue sections of mice 7 days after intravenous injection
with carbon nanomaterials at 25 mg/g b.w. Carbon nanomaterials are indicated by arrows. Tissue sections were stained with hematoxylin. The scale




PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32893In our study, CNTs in the lungs formed aggregates of
approximately the same diameter as the blood vessels and were
trapped in a manner similar to a pulmonary embolism, clogging the
blood vessels. Thus, the main cause of death of the mice injected
with high dose CNTs is attributed to the mechanical obstruction of
the blood vessels in the lungs, possibly leading to acute heart failure.
By contrast, very few carbon nanomaterials were found in the CNC
or C60 lung tissue sections. The CNC and C60 nanoparticles that
remained in the lungs were extremely small, and most of these small
nanoparticles may have escaped the highly vascularized lungs and
traveled to other organs, while the aggregated MWCNTs and
SWCNTs were easily trapped in the lungs. Consistent with previous
reports, large aggregates of CNTs are the main concern for the
biosafety of this material [20]. What remains unclear, however, is
why there was high toxicity after the C60 injections despite the high
clearance rate and the lack of an immune response. Lung and other
vital organ tissue sections of the C60 group did not show any
retention at any dose. Although C60 was absent from our tissue
sections, we cannot rule out C60 retention due to the extreme small
dimensions of this nanoparticle. Indeed, a recent study quantified
C60 retention following intravenous injection in rats using liquid
chromatography[38]. Their results show high acute retentionofthe
particles in the vital organs, particularly the lung one day following
injection, which decreased over the course of 4 weeks. Together
with other studies that have reported C60 toxicity, it is reasonable
that C60 fuller is lethal following intravenous injection.
The inflammatory response was consistent with other studies
that CNTs or other forms of fullerene did not elicit an
inflammatory response in any tissue, although the nanomaterials
were distributed throughout the animal [20]. Both systemic and
local tissue studies showed that cytokine levels were at the same
level as normal saline treated groups at the acute phase. LPS
groups were significantly higher in both IL-1b and IL-6 levels.
Long-term studies are required to further understand whether
these nanomaterials trigger chronic inflammation. However,
similar to our findings, a recent study by Burke et al provided
similar insight into the toxicity profile of CNTs [39]. MWCNTs
injected at similar dosage were lethal in the acute stage, mainly by
obstructing blood vessels in the lung. Furthermore, non-functio-
nalized MWCNTs increased vWF and D-dimer levels following
systemic injection, and reduced platelet count. Additionally,
functionalization is effective in attenuating coagulation effects of
MWCNTs.
To our knowledge, there has not been a single study that had
comprehensively investigated the in vivo effect of different carbon
nanomaterials injected intravenously. Most past studies aimed to
characterize production plant safety by studying the pulmonary
toxicity of carbon nanomaterials encountered through intratra-
cheal instillation [9]. In addition, we included a novel carbon
allotrope, CNC in this study. Here, we investigated the in vivo
toxicity of raw, non-modified carbon nanomaterials delivered
intravenously, hoping to gain an understanding of the dynamics of
these nanomaterials in vivo. Nanotechnology has offered a wealth
of possibilities for enhanced drug therapy to deliver therapeutic
Figure 5. Systemic inflammatory cytokine level in mice. Serum
and lung tissue IL-1b and IL-6 levels 6 hours post-injection with carbon
nanomaterials. There is no significant difference between all groups
(except LPS). n=5, P=0.0029 (serum, IL-1b); n=5, P=0.0001 (serum, IL-
6); n=4. *P,0.05, **P,0.01, ***P,0.001 significantly different com-
pared with the LPS group. NS, normal saline; PVA, polyvinyl alcohol;
CNCs, carbon nanocapsules; C60,C 60 fullerene; M, multi-walled carbon
nanotubes; S, single-walled carbon nanotubes.
doi:10.1371/journal.pone.0032893.g005
Figure 6. Lung tissue inflammatory cytokine level in mice. Lung
tissue IL-1b and IL-6 levels 6 hours post-injection with carbon
nanomaterials. There is no significant difference between all groups
(except LPS). Lung-tissue cytokine levels were normalized to the total
protein level determined using a BCA kit (Pierce, USA). n=5,
***P=0.0001 (lung tissue, IL-1b); n=4, P=0.0001 (lung tissue, IL-6),
compared to the LPS group. NS, normal saline; PVA, polyvinyl alcohol;
CNCs, carbon nanocapsules; C60,C 60 fullerene; M, multi-walled carbon
nanotubes; S, single-walled carbon nanotubes.
doi:10.1371/journal.pone.0032893.g006
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32893treatment. However, nanotoxicity must be well characterized
before this technology can be used safely and effectively. Our
results show that although certain properties of CNTs have
allowed propelled this material to succeed in applications in
sensors, circuitry, and structural components, the aggregating
property of CNTs inhibit safe usage in drug delivery.
In this preliminary study, CNCs have been shown to be more
biocompatible following intravenous injection and may emerge in
the future for drug delivery purposes. These CNCs have already
been functionalized to further enhance dispersion rates. In the
future, these functionalized CNCs represent a novel carbon
allotrope as a solution to the aggregating issue of CNTs, providing
an alternate research opportunity towards drug delivery. Using
current established methods, crosslinkers can be employed to
conjugate antibodies, proteins, peptides, or small molecules onto
functionalized CNCs for drug delivery purposes. We envision
CNCs as a potential alternative to CNTs in the application of
intravenous drug delivery.
Supporting Information
Figure S1 Carbon nanomaterial dispersions before and
after sonication and shaking. SWCNTs, MWCNTs, and
CNCs better dispersed after sonication. C60 was too dense for
sonication to have an effect. All nanomaterial dispersions were
both sonicated and hand-shaken prior to injections. CNCs, carbon
nanocapsules; C60, C60 fullerene; MWCNTs, multi-walled
carbon nanotubes; SWCNTs, single-walled carbon nanotubes.
(TIF)
Figure S2 Urine collected from mice 6 hours post-
injection with carbon nanomaterials at 25 mg/g. Urine
samples revealed that some CNCs, C60, and MWCNTs can be
cleared from the body as soon as 6 hours post-injection. No
evidence of clearance of SWCNTs was observed throughout the
study. PVA, polyvinyl alcohol; CNCs, carbon nanocapsules; C60,
C60 fullerene; MWCNTs, multi-walled carbon nanotubes;
SWCNTs, single-walled carbon nanotubes.
(TIF)
Figure S3 Lung homogenate lysate after centrifugation
at 14,000 rpm for 20 minutes. SWCNT and MWCNT
lysates were much darker than those of all other groups.
PVA, polyvinyl alcohol; CNCs, carbon nanocapsules; C60, C60
fullerene; MWCNTs, multi-walled carbon nanotubes; SWCNTs,
single-walled carbon nanotubes.
(TIF)
Table S1 Table comparing physical properties of the
different nanomaterials used in the study.
(DOC)
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